Close Menu

non-small cell lung cancer

Researchers showed benefit from chemotherapy in patients classified as high risk by the test, independent of their EGFR mutation status.

The study will assess the safety and anti-tumor activity of the IL-7 agent and the checkpoint inhibitor combination for patients with PD-L1-expressing NSCLC. 

The company submitted data from the ADAURA study, and the agency is slated to issue a decision on the application by the first quarter in 2021.

The Phase Ib trial assessed the bespoke cancer vaccine NEO-PV-01 plus Opdivo as a treatment for patients with advanced melanoma, NSCLC, and bladder cancer.

A pooled analysis of clinical trials and real-world data shows that the anti-tumor activity of Boehringer Ingelheim's TKI is unaffected by patients' ethnicity.

Stanford and Memorial Sloan Kettering researchers have developed a multi-modal and multi-timepoint biomarker approach to predict therapeutic benefit in lung cancer cases.

The company said data from the Phase II portion of the CodeBreak-100 study in KRAS-mutated lung cancer patients was positive and may be registrational.

The randomized trial will assess the glutaminase inhibitor plus standard-of-care versus standard-of-care alone in patients with KEAP1- or NRF2-mutated tumors.

In two studies at ESMO, researchers demonstrated the ability of combined biomarker approaches to predict the efficacy of immune checkpoint inhibitors.

Phase I data at ESMO suggested that the experimental drug may be particularly effective in KRAS G12C-mutated lung and colon cancers.

Pages